Portola Pharmaceuticals Культура компании

Mr. William Lis, also known as Bill, has been the Chief Executive Officer of Portola Pharmaceuticals, Inc. since April 2010 and serves as its President. Mr. Lis served as Chief Operating Officer of Portola Pharmaceuticals Inc. He served as Vice President of Business and Commercial Development at Portola Pharmaceuticals, Inc. since June 2008. He has over 17 years of experience in biopharmaceutical and medical device sales & marketing, medical affairs and business development. From 2005 to 2008 he served as Vice President, Business and New Product Development, Scios, Inc. (A Johnson and Johnson Company) where he was responsible for cardiovascular business licensing strategies and activities and commercial operations. Mr. Lis led successful in-licensing activities and pre-market and commercial infrastructure development for Xarelto(R) (rivaroxaban) a Phase III drug candidate, filed for EMEA regulatory approval. Prior to joining Scios, Mr. Lis served as Director of Marketing and New Products, Millennium Pharmaceuticals, Inc. where he held positions of increasing leadership, including the management of marketing activities for Integrilin(R) (eptifibatide), a best in class antithrombotic drug. He served at Rhone Poulenc Rorer and Ethicon Endo Surgery and was involved in the launch and commercialization of several products, including Lovenox(R) (enoxaparin). He has been a Director of Portola Pharmaceuticals, Inc. since April 2010. Mr. Lis holds a B.S. degree in Finance from the University of Maryland.

Mr. Tao Fu has been the Chief Commercial & Business Officer and Executive Vice President at Portola Pharmaceuticals, Inc. since June 2015. At Portola, Mr. Fu is responsible for its commercial operations and business development. Mr. Fu served as Vice President and Head of mergers and acquisitions and alliance management at Bristol-Myers Squibb (BMS). At BMS, Mr. Fu was responsible for its corporate development, alliance management and venture activities. Prior to that, he served as Vice President of business development at Janssen, the pharmaceuticals group of Johnson & Johnson. In his tenure there, he was responsible for the execution of the U.S. license and collaboration agreement with Bayer for the Factor Xa inhibitor XARELTO?? (rivaroxaban). He also has experience in business development, commercial strategy and management consulting with Scios Inc. and also with McKinsey & Company and Becton Dickinson. He has been an Independent Director at ZAI Lab Limited since 2017. Mr. Fu is a chartered financial analyst. Mr. Fu holds an M.S. in biology from the University of Rochester and an M.B.A in finance and marketing from Vanderbilt University. He did his undergraduate studies in biology at Tsinghua University.

Mr. Jeet Mahal has been the Vice President of Business Development at Portola Pharmaceuticals, Inc. since January 2013. Mr. Mahal served as Senior Vice President of Pharmaceutical Development at Portola Pharmaceuticals, Inc. Mr. Mahal joined Portola in 2008 and served as its Vice President of Business Development since December 2009. He is responsible for in-licensing, out-licensing and alliance management activities across the development portfolio. Mr. Mahal served as Director of Business and New Product Development at Scios Inc. (Johnson & Johnson) where he led commercial life cycle activities for Xarelto and commercial analysis for U.S. cardiovascular in-licensing. Prior to Scios, Mr. Mahal served as a Managing Consultant for Navigant Consulting??? s Life Sciences practice. He started his career as a development scientist at COR Therapeutics working on a number of the company??? s pipeline products, including Integrilin from Phase 2 to New Drug Application. Mr. Mahal holds a BA in biological sciences from the University of California at Berkeley, an MBA from the Fuqua School of Business at Duke University, a master??? s degree in biology from Illinois Institute of Technology and a master??? s degree in engineering, computer science from North Carolina State University.

Ms. Mardi C. Dier has been the Chief Financial Officer and Executive Vice President of Portola Pharmaceuticals, Inc. since August 2006. Ms. Dier has overseen the development of the accounting, finance, global supply chain, investor relations, communications, IT and facilities functions and has led the raising of over $1.25 billion in capital. She served as Senior Vice President of Portola Pharmaceuticals since August 2006. She has significant financial and investor relations experience. She has over 25 years of financial management experience in the biotechnology industry. She served as a Vice President of Investor Relations at Chiron Corporation from 2003 to April 2006. While at Chiron, her responsibilities included developing relationships with Wall Street and communicating Chiron Corporation's financial performance and growth strategy for more than 30 commercial products as well as for a number of pipeline opportunities. Prior to joining Chiron, She served as a Director in the west coast life sciences practice at Prudential Securities, where she focused on client development, equity underwriting and mergers and acquisitions. Ms. Dier was previously at KPMG Peat Marwick in the audit department. She has been a Director of Adamas Pharmaceuticals, Inc. since October 11, 2017. In 2013, Ms. Dier was recognized as one of the most influential Bay Area business women by the San Francisco Business Times and was a finalist for its Bay Area Chief Financial Officer of the Year Award. Ms. Dier holds an MBA degree from The Anderson School at the University of California, Los Angeles and a B.S. degree in Biology from Stanford University.

Dr. R. Andrew Ramelmeier, also known as Andy, Ph.D. has been Senior Vice President and Head of Technical Operations & Manufacturing at Sangamo Therapeutics, Inc. since January 1, 2018. Dr. Ramelmeier served as Senior Vice President of Biologics Technical Operations at Portola Pharmaceuticals, Inc. since October 2014. He served as Vice President of Manufacturing & Process Development of BioMarin Pharmaceutical Inc. from September 2006 to March 2014. He has 20 years of experience and a strong foundation in the development and manufacturing of biopharmaceuticals, including monoclonal antibodies, vaccines, enzymes and other therapeutic proteins. His technical expertise spans from cell culture and fermentation through purification, formulation and parenteral fill/finish. Dr. Ramelmeier joined BioMarin in September 2006 and his responsibilities included oversight of manufacturing, manufacturing sciences, process development and facilities. Dr. Ramelmeier served as Vice President of Process Sciences of the Global Biologics Supply Chain (formerly, Centocor Inc.) at Johnson & Johnson. In this role, he oversaw technical support of J&J's BioPharm manufacturing plants, including process validation and tech transfer of new and existing products, regulatory inspections and process improvements. From 2001 to 2005, he served as Executive Director of Pharmaceutical Development at Centocor, where he was responsible for pilot plant operations, clinical and toxicology supplies and pilot-scale process development. In this role, his team increased clinical manufacturing capacity three-fold and developed scale-up capability to meet the growing needs of the BioPharm business in J&J. Earlier in his career, he served as Senior Research Fellow, Bioprocess Research and Development at Merck & Co. Dr. Ramelmeier received his Ph.D. degree in Chemical Engineering at the University of California, Berkeley and a B.S. degree in Chemical Engineering from Johns Hopkins University. He conducted post-doctoral work at the Institute for Enzyme Technology in Germany.

Dr. John T. Curnutte, M.D., Ph.D., has been an Executive Vice President of Research & Development at Portola Pharmaceuticals, Inc. since February 2011. At Portola, Dr. Curnutte oversees all of it's R&D operations, including discovery research, development, clinical operations and regulatory affairs. Dr. Curnutte served as Chief Executive Officer of 3-V Biosciences, Inc. He served as President of Schering-Plough Biopharma, a unit of Schering-plough Corp. since June 1, 2005. Dr. Curnutte joined Schering-Plough Biopharma (formerly DNAX Research Institute) from Genentech, where he directed the activities of immunology, pathology and antibody technology and made significant contributions to the development of therapeutic and research monoclonal antibodies. He served as Senior Director of Genentech Inc. Devoting more than 30 years of his life to understanding the normal and abnormal functions of the immune system, Dr. Curnutte has helped hundreds of children and their families fight CGD-related infections and significantly improve the outlook of this progressive and often fatal disease. This is evident in his pro bono medical practice, which allows him to consult with patients, physicians and genetic counselors throughout the U.S. and Canada. Offering his time as a gift to the field of medicine, Dr. Curnutte facilitates cell and DNA testing for CGD families across the country. Specializing in pediatric hematology and oncology, he continues to serves as a medical staff member at Stanford University Medical Center and as an Adjunct Clinical Professor of Pediatrics at Stanford University School of Medicine. After serving on the faculty of the University of Michigan in Ann Arbor, Dr. Curnutte began focusing his research and clinical practice on immune deficiencies involving white blood cells. Intrigued by the potential of combining basic science with clinical medicine, he continued to integrate his scientific training in biochemistry with faculty, clinical and corporate posts at The Scripps Research Institute, the Lucile Salter Packard Children's Hospital at Stanford and Genentech. During this time, he was drawn to work with children who have cancer and blood diseases and he soon narrowed his focus on chronic granulomatous disease (CGD), an inherited disorder of the neutrophil function. He has been an Independent Director of diaDexus, Inc., since February 24, 2015. He has been Director of Pliant Therapeutics, Inc. since September 26, 2017. He served as a Director at 3-V Biosciences, Inc. Dr. Curnutte received his Ph.D. degree in biological chemistry and M.D. from Harvard Medical School. He holds an A.B. in biochemistry and molecular biology from Harvard University. He did his postdoctoral training in pediatrics (Massachusetts General Hospital) and pediatric hematology/oncology (Boston Children's Hospital and the Dana-Farber Cancer Institute).

Mardi Dier serves as the EVP & CFO of Portola Pharmaceuticals. Mardi started at Portola Pharmaceuticals in August of 2006. Mardi currently resides in San Francisco Bay Area.

Jack Lawrence serves as the Senior Vice President and Chief Medical Officer of Portola Pharmaceuticals. Jack started at Portola Pharmaceuticals in November of 2017. Jack currently resides in Greater New York City Area.